Pfizer FY2026 Earnings Forecast Raised by Erste Group Bank

Pfizer Inc. (NYSE:PFE) – Equities research analysts at Erste Group Bank boosted their FY2026 earnings per share (EPS) estimates for Pfizer in a report released on Thursday, October 8th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will post earnings per share of $2.97 for the year, up from their previous forecast of $2.96. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the company earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS.

A number of other equities research analysts also recently weighed in on PFE. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. BMO Capital Markets lowered their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday. Finally, Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Five analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.72.

Pfizer Stock Up 3.0%

Shares of NYSE:PFE opened at $29.22 on Tuesday. Pfizer has a one year low of $23.62 and a one year high of $29.49. The company has a 50 day moving average of $27.88 and a 200-day moving average of $26.53. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The stock has a market cap of $166.53 billion, a price-to-earnings ratio of 9.30, a P/E/G ratio of 1.93 and a beta of 0.32.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 5.9%. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Hedge Funds Weigh In On Pfizer

Institutional investors have recently modified their holdings of the stock. Retirement Wealth Solutions LLC boosted its position in Pfizer by 144.6% during the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 509 shares during the period. Evolution Wealth Management Inc. raised its position in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares during the period. Keb Asset Management LLC bought a new position in shares of Pfizer in the second quarter valued at about $26,000. Field & Main Bank acquired a new stake in shares of Pfizer during the 2nd quarter worth about $27,000. Finally, Global Trust Asset Management LLC lifted its stake in shares of Pfizer by 126.7% during the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 650 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer said it will present data from more than 50 abstracts at IDWeek 2026, including updates on its Lyme vaccine, next-generation pneumococcal vaccine, RSV and COVID-19 programs. The breadth of the upcoming data could reinforce confidence in Pfizer’s infectious-disease pipeline. Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
• Positive Sentiment: A next-generation pneumococcal vaccine has entered a key Phase 3 trial, potentially expanding Pfizer’s future vaccine revenue opportunities. Pfizer’s Next-Gen Pneumococcal Shot Enters Key Phase 3 Test
• Positive Sentiment: Pfizer entered a research collaboration and licensing agreement with Enodia Therapeutics to discover and develop Sec61-targeting small molecules. The deal adds another external innovation program to Pfizer’s pipeline, although commercial benefits are likely years away. Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer
• Positive Sentiment: Unusually heavy call-option activity and recent purchases by several Pfizer insiders may have supported bullish trading sentiment. Investors are also attracted to the roughly 6% dividend yield and the declared quarterly dividend of $0.43 per share.
• Neutral Sentiment: Pfizer’s latest reported quarter exceeded earnings and revenue expectations, and management’s 2026 EPS guidance is $2.80–$3.00. However, the company’s outlook remains dependent on pipeline execution and replacing pandemic-related revenue declines.
• Negative Sentiment: The dividend’s sustainability remains a concern: commentary highlighted a payout ratio above reported earnings, while several analyst price targets cluster between $25 and $28—below the current share price. This could limit upside despite the attractive income yield.

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.